Tyra Biosciences Inc’s recently made public that its Director GILLA KAPLAN acquired Company’s shares for reported $104.0 on Jun 17 ’25. In the deal valued at $10.35 per share,10 shares were bought.
Then, RA CAPITAL MANAGEMENT, L.P. bought 120,167 shares, generating $1,225,703 in total proceeds. Upon buying the shares at $10.20, the Director now owns 10,247,478 shares.
Before that, RA CAPITAL MANAGEMENT, L.P. bought 31,307 shares. Tyra Biosciences Inc shares valued at $319,331 were divested by the Director at a price of $10.20 per share. As a result of the transaction, RA CAPITAL MANAGEMENT, L.P. now holds 10,127,311 shares, worth roughly $97.12 million.
A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. BofA Securities also remained covering TYRA and has increased its forecast on October 18, 2024 with a “Buy” recommendation from previously “Neutral” rating. Piper Sandler started covering the stock on August 15, 2024. It rated TYRA as “an Overweight”.
Price Performance Review of TYRA
On Tuesday, Tyra Biosciences Inc [NASDAQ:TYRA] saw its stock fall -6.16% to $9.59. Over the last five days, the stock has lost -10.46%. Tyra Biosciences Inc shares have fallen nearly -31.01% since the year began. Nevertheless, the stocks have fallen -51.69% over the past one year. While a 52-week high of $29.60 was reached on 01/15/25, a 52-week low of $6.42 was recorded on 04/09/25.
Levels Of Support And Resistance For TYRA Stock
The 24-hour chart illustrates a support level at 9.29, which if violated will result in even more drops to 8.99. On the upside, there is a resistance level at 10.16. A further resistance level may holdings at 10.73.
